$NVAX

$10.02 +$0.62 (6.54%) Live

$NVAX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$NVAX Management Team

Mr. James Kelly

Chief Financial Officer

Executive Vice President

Treasurer

Age 59

Compensation $1.829M USD

Sex Male

Mr. Mark Casey

Executive Vice President

Chief Legal Officer

Company Secretary

Age 62

Compensation $1.062M USD

Sex Male

Dr. Ruxandra Draghia-Akli

Executive Vice President

Head of Research & Development

Age 60

Compensation -

Sex Female

Ms. Elaine O'hara

Executive Vice President

Chief Strategy Officer

Age 57

Compensation $1.638M USD

Sex Female

Dr. Robert Walker

Senior Vice President

Chief Medical Officer

Age -

Compensation -

Sex Male

Ms. Margaret Mcglynn

Independent Chairman of the Board

Age 65

Compensation $466.1K USD

Sex Female

Mr. John Jacobs

President

Chief Executive Officer

Director

Age 58

Compensation $5.087M USD

Sex Male

Name / Title	Age	Compensation	Sex
Mr. James Kelly Chief Financial Officer Executive Vice President Treasurer	59	$1.829M USD	Male
Mr. Mark Casey Executive Vice President Chief Legal Officer Company Secretary	62	$1.062M USD	Male
Dr. Ruxandra Draghia-Akli Executive Vice President Head of Research & Development	60	-	Female
Ms. Elaine O'hara Executive Vice President Chief Strategy Officer	57	$1.638M USD	Female
Dr. Robert Walker Senior Vice President Chief Medical Officer	-	-	Male
Ms. Margaret Mcglynn Independent Chairman of the Board	65	$466.1K USD	Female
Mr. John Jacobs President Chief Executive Officer Director	58	$5.087M USD	Male

Board of Directors

From the proxy statement filed Apr 27, 2026

Directors

serving now

Independent

8 of 9

stated in the proxy

Average tenure

5.7 years

from year joined

CEO also chairs the board

David Mott

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
John C. Jacobs CEO	59	2023 3 years	Not independent	None stated	None stated	Paid as CEO
Gregg H. Alton, J.D.	60	2020 6 years	Independent	Audit Nominating and Corporate Governance Capital Allocation	Corcept Therapeutics	$355,091
Richard J. Rodgers	59	2022 4 years	Independent	Compensation Capital Allocation	Ardelyx, Inc.	$375,449
Richard H. Douglas, Ph.D.	73	2010 16 years	Independent	Audit Research and Development	Alderya Therapeutics, Inc.	$364,462
Margaret G. McGlynn, R.Ph.	66	2020 6 years	Independent	Nominating and Corporate Governance · Chair	Amicus Therapeutics	$402,278
David Mott Board chair	60	2020 6 years	Independent	Compensation · Chair	Ardelyx	$365,591
Rachel K. King	66	2018 8 years	Independent	Compensation Nominating and Corporate Governance	Fulcrum Therapeutics	$353,091
John W. Shiver, Ph.D.	68	2025 1 year	Independent	Compensation Research and Development · Chair	None stated	$516,545
Charles W. Newton	55	2025 1 year	Independent	Audit Nominating and Corporate Governance Capital Allocation · Chair	Coherus Oncology	$491,949

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 27, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Comments

Company Executives

$NVAX Management Team

Mr. James Kelly

Mr. Mark Casey

Dr. Ruxandra Draghia-Akli

Ms. Elaine O'hara

Dr. Robert Walker

Ms. Margaret Mcglynn

Mr. John Jacobs

Board of Directors

Related-party transactions

No related-party transactions disclosed